Journal
CHEST
Volume 143, Issue 3, Pages 856-858Publisher
AMER COLL CHEST PHYSICIANS
DOI: 10.1378/chest.12-0859
Keywords
-
Categories
Funding
- GlaxoSmithKline Canada
- Canada Research Chair in Airway Inflammometry
- Canadian Institutes of Health Research
- F. Hoffmann-La Roche Ltd.
Ask authors/readers for more resources
Airway inflammation is considered a central component of asthma and, therefore, international guidelines recommend antiinflammatory medications. We describe the clinical history of a 34-year-old woman with airway hyperresponsiveness and asthma who had a reduced ability to mount an inflammatory response due to two unrelated and rare genetic conditions: Fanconi anemia and incontinentia pigmenti. Absence of eosinophils in blood and sputum led to a successful reduction in the dose of corticosteroids without loss of asthma control demonstrating the clinical utility of monitoring treatment using biomarkers and the importance of recognizing the components of airway diseases that contribute to symptoms. CHEST 2013; 143(3):856-858
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available